期刊文献+

干扰素联合利巴韦林治疗慢性丙肝35例抗病毒效果及T细胞亚群变化 被引量:7

下载PDF
导出
摘要 目的:观察干扰素联合利巴韦林治疗慢性丙型肝炎抗病毒效果及T细胞亚群变化。方法:慢性丙型肝炎35例应用干扰素联合利巴韦林治疗,干扰素300~500万,隔日肌肉注射,利巴韦林800~1 000mg/d,疗程24周。用药前后定期检查肝功能、HCV RNA、T细胞亚群。结果:与治疗前比较,治疗24周后患者血清HCV RNA滴度由4.2±1.1cp/ml下降到3.2±1.6cp/ml,CD4+由(33.6±7.5)%上升到(37.0±5.1)%,CD4+/CD8+由(1.31±0.21)%上升到(1.52±0.30)%,3项指标治疗前后比较差异有统计学意义(P<0.05)。结论:干扰素α-2b加利巴韦林治疗慢性丙型肝炎,既能抑制HCV RNA复制,又可调节细胞免疫功能。
出处 《交通医学》 2011年第1期71-72,共2页 Medical Journal of Communications
  • 相关文献

参考文献5

二级参考文献25

  • 1丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量:735
  • 2王宇明.干扰素治疗丙型肝炎的近况[J].国外医学(流行病学.传染病学分册),1994,21(6):253-258. 被引量:4
  • 3[1]Mele L,Muratori P,Cassani F,et al.Circulating non-organ specific autoantibodies (NOSA) and cryoglobulins (CG) in HCV-related chronic liver disease(CLD)[J].Journal of Hepatology,2003,38(2):157-159.
  • 4[3]Lohr HF,Grerken G,Michel G,et al.In vitro secretion of anti-GOR protein and anti-hepatitis C virus antibodies in patients with hepatitis C[J].Gastroenterology,1994,107:1443-1445.
  • 5[4]Quiroga JA,Pardo M,Navas S,et al.Patterns of immune responses to the host-encoded GOR and hepatitis C virus core-derived epitopes with relation to hepatitis C virernia.genotypes,and liver disease severity[J].J Infect Dis,1996,173:300-302.
  • 6[5]Alessandro A,Clodoveo F,Alessandro P,et al.Thyroid disorders in chronic hepatitis C[J].The American Journal of Medicine,2004,117(1):10-12.
  • 7Camma C, Bruno S, Schepis F, et al. Retreatment with interferon plus ribavirin of chronic hepatitis C non- responders to interferon monotherapy: a meta- analysis of individual patient data[ J ]. Gut, 2002,51:864-869.
  • 8Papatheodoridis GV, Papadimitropoulos VC, Hsdziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus- reated cirrhosis: a meta- analysis[J] .Aliment Pnarmaool Ther, 2001,15:689- 698.
  • 9Kjaergard LL, Krogsgaard K, Gluud C. Interfern alfa with or without ribavirin for chronic hepatitis C: systematic review of randonmised trials[J].BMJ, 2001,323:1151 - 1155.
  • 10Alberti A, Benvegnu L. Management of hepatitis[J] .J Hepatol, 2003,38(Suppl1): S1014 - S1 18.

共引文献14741

同被引文献43

  • 1吴安平,樊万虎,张树林.佩乐能联合利巴韦林治疗慢性丙型病毒性肝炎副作用分析[J].中国现代医药杂志,2007,9(4):104-106. 被引量:3
  • 2Kathleen B, Schwarz, Regino P, et al.The Combination of Ribavirin and Peginterferon Is Superior to Peginterferon and Placebo for Children and Adolescents With Chronic Hepatitis C[J].Gastroenterology, 2011,140 (2) 450-458.
  • 3Wang-Sheng Ko, Chih-Hung Guo, Guoo-Shyng W.Hsu, et al.The effect of zinc supplementation on the treatment of chronic hepatitis C patient.q with interferon and ribavirin[]l.Clinical Biochemistry, 2005,38 ( 7 ): 614-620.
  • 4唐美芳,杨俊文,骆成榆.丙型肝炎基因型病毒量及肝损伤程度与a干扰素疗效的关系[J].临床肝胆病杂志,2010,17(12):289-290.
  • 5Lee SD, Yu ML, Cheng PN, et al. Comparison of a 6 month course peglntefferon alpha-2b plus ribavirin and interferon alpha-2a plus ribaviria in treating Chinese patients with chronic hepatitis C in Taiwan[ J]. J Vfial Hepat,2010,12(3) :283-291.
  • 6European Association for the Study of the Liver. EASL Clinical Practice Guidelines management of hepatitis C virus infection [ j ]. Hepato1,2011,55 (2) :245 -264.
  • 7孙鹏.聚乙二醇干扰素oL-2a联合利巴韦林对慢性丙肝[J]现代医院,2011,11(31):63-65.
  • 8Lee MH, Yang HI, Jen CL, et al. Community and personal risk factors for hepatitis C virus infection: a survey of 23,820 residents in Taiwan in 1991-2011 [J]. Gut,2011,60(5) :688-694.
  • 9汪静,蔡立敏.聚乙二醇干扰素α-2b联合利巴韦林治疗慢性丙肝的护理体会[J].护理实践与研究,2010,7(9):43-44. 被引量:9
  • 10严喜章.PEG-IFNα联合利巴韦林治疗慢性丙型肝炎37例临床观察[J].山东医药,2010,50(23):89-90. 被引量:2

引证文献7

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部